PATIENTS AND METHODS Patients and controls
The enrollment of HD patients to the study started in January 2009 and was completed in May 2014. Twenty-one dialysis centers participated in the study. Demographic data (sex, metrical age), clinical data (causes of ESRD, comorbidities, age at the start of RRT, length of RRT, frequency of parathyroidectomy and treatment with cinacalcet, response rate to hepatitis B vaccination, prevalence of HBV/HCV infections, frequency of renal transplantation, causes of death), laboratory parameters (liver enzymes, calciumphosphorus balance parameters, HBV/HCV seromarkers), and blood samples for genotyping were collected and updated every year (the last revision was done in August -September, 2014). The adherence of dialysis physicians to collecting specific patient data varied from 100% to 65% for γ-glutamyltranspeptidase (GGT), which is not obligatorily tested in dialysis facilities.
Controls (n = 378) were recruited from blood donors and healthy volunteers unrelated to patients and to one another. They lived in the same geographical region as patients.
Genotyping IL13, IL4R, IL12A, IL28B, GC rs2298849, GC rs1155563, RXRA rs10776909, and RXRA rs10881578 polymorphisms were genotyped using a high-resolution melting curve analysis. Polymerase chain reaction-restriction fragment length polymorphism was used for IL18, IL12B, MCP1, GC rs7041, VDR rs2228570, VDR rs1544410, and RXRA rs749759 genotyping. For quality control, approximately 10% of the randomly chosen samples were regenotyped. Samples with ambiguous results were excluded from further statistical analyses.
Statistical analysis
The results were presented as percentage for categorical variables, as mean with 1 standard deviation for normally distributed continuous variables, or as median with range for not normally distributed continuous variables as tested by the Shapiro-Wilk test.
Survival probability since the start of RRT was analyzed with respect to the tested polymorphic variants using dominant, recessive, and additive models of inheritance. The Kaplan-Meier method with the subsequent log-rank test was used to estimate significance of differences in cumulative proportion surviving curves characterizing the genotype groups in each model of inheritance. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a Cox proportional hazard model to show the effect of the genotype on the risk of death (all-cause mortality). The Cox model was applied to show the significance of polymorphic variants in the prediction of survival among the collected demographic, clinical, and laboratory data. If an association between the tested polymorphic variants and survival probability was significant (P values for both HR and the log-rank test was less than 0.05), we tried to establish which phenotype was associated with related to type 1 and 2 diabetes, 2-4 diabetic nephropathy, 4 lupus nephritis, 5 atherosclerosis, 6 and graft-versus-host disease, 7 whereas Th2 supremacy was shown in infections, 2,8 allergy, 9 asthma, 3 and cancers. 30 However, the above effects do not always result in differences in circulating cytokines in in-vivo studies in which vitamin D is given to patients. 31 Deviations from the T-cell cytokine balance [32] [33] [34] and low plasma vitamin D concentrations [35] [36] [37] are related to cardiovascular events 34,37 as well as altered immunocompetence during infections 32, 35 and vaccinations. 33, 36 Serum parathyroid hormone (PTH) levels are dependent on serum vitamin D concentrations, 38 and T cells are implicated in the mechanism of the PTH action in the bone. 39 We aimed to check a frequency distribution of polymorphic variants of the genes encoding cytokines/ILs related to Th1 and Th2 cells (IL18 rs360719, IL13 rs20541, IL4R rs1805015, IL12A rs568408, IL12B rs3212227, IL28B rs8099917, IL28B rs12979860, and MCP1 rs1024611) as well as polymorphisms of the vitamin D pathway genes (the vitamin D-binding protein gene, also referred to as the group-specific component gene: GC rs2298849, GC rs1155563, GC rs7041; vitamin D receptor gene: VDR rs2228570, VDR rs1544410; and retinoid X receptor alpha gene: RXRA rs10 776 909, RXRA rs10881578, and RXRA rs749759) in relation to survival probability of patients with ESRD requiring renal replacement therapy (RRT).
returned to HD treatment after irreversible graft failure). There were 437 deaths during the study period. Two individuals died in accidents, other causes of death were clear in 386 cases. Four main causes of death included chronic or acute cardiac diseases (45.9%), cerebral stroke (15.0%), sepsis or pneumonia (10.9%), and cancer (10.6%).
Survival probability since the start of RRT in this group was negatively associated with age at the start of RRT (P <0.0001), presence of diabetic nephropathy (P <0.0001), presence of CAD (P <0.0001), history of MI (P < 0.0001), and serum GGT activity (P = 0.02). Chronic glomerulonephritis as the cause of ESRD (P <0.0001), a history of renal transplantation (P < 0.0001), and development of anti-HB antibodies in response to hepatitis B vaccination or HBV infection (P = 0.02) increased the survival probability.
Genotype frequencies in patients and controls A frequency distribution of the tested single nucleotide polymorphisms (SNPs) did not differ between the experimental and control groups (P trend >0.05).
Th cell-related cytokine gene polymorphisms as predictors of survival probability The only polymorphisms of Th cell-related cytokine genes associated with survival probability of the examined patients were those of IL13 and IL28B.
Patients carrying the IL13 minor T allele (CT and TT genotypes) had an increased risk of death since the start of RRT compared with IL13 CC patients (FIGURE 1). The IL13 T allele was an independent predictor of death since the start of RRT (HR, 1.28; CI, 1.01-1.63; P = 0.04) also among other variables: older age at the start of RRT (HR, 1.03; 95% CI, 1.02-1.04; P <0.0001), CAD this specific gene calculating odds ratios (ORs) with 95% CIs. All probabilities were 2-tailed. A P value of less than 0.05 was considered significant. The Bonferroni correction for multiple comparisons was used, where appropriate.
The survival analysis was performed in the whole groups with determined genotypes and also in the groups divided according to demographic/clinical parameters, where reasonable.
A statistical analysis was performed using Graph-Pad InStat 3.10, 32 bit for Windows, created 
HR, hazard ratio
We also examined whether IL28B SNPs may predict survival since the start of RRT in patients with a history of HBV or HCV infection. No association was found in the group of infected patients, while it was revealed in patients without a history of those infections. HBV-or HCV-negative patients carrying the IL28B rs12979860 TT genotype had an increased risk of death compared with IL28B CC+CT carriers (FIGURE 3) . HBVor HCV-negative IL28B rs8099917 GG carriers showed an increased risk of death compared with GT+TT carriers (FIGURE 4) and TT carriers (FIGURE 5). IL28B rs12979860 was not significant in the model composed of the same variables as for IL13 (HR, 1.41; 95% CI, 0.93-2.15; P = 0.1); IL28B rs8099917 showed borderline significance (HR, 1.90; 95% CI, 0.96-3.75; P = 0.07). The prevalence of CAD differed significantly among patients carrying the IL28B rs12979860 TT genotype compared with CC and CT carriers (OR, 1.87; 95% CI, 1.14-3.09; P = 0.01; significance was maintained with a Bonferroni-corrected P value of 0.017) as well as with CC carriers (OR, 1.91; 95% CI, 1.16-3.15; P = 0.01, significance was maintained with (HR, 1.86; 95% CI, 1.44-2.40; P <0.0001), development of anti-HB antibodies in response to hepatitis B vaccination or HBV infection (HR, 0.72; 95% CI, 0.55-0.95; P = 0.02), chronic glomerulonephritis (HR, 0.67; 95% CI, 0.44-1.00; P = 0.05), and diabetic nephropathy (HR, 1.22; 95% CI, 0.93-1.59; P = 0.2). A P value for this Cox model was less than 0.00001. No significant associations between IL13 polymorphisms and patient data were shown (TABLE 1). The negative association of the T allele with survival probability was more pronounced in men (log-rank test, P = 0.03; HR, 1.40; 95% CI, 1.03-1.90; P = 0.03; n = 586) than in women (log-rank test, P = 0.06; HR, 1.41; 95% CI, 0.98-2.01; P = 0.06; n = 446).
In the entire study group, there were no significant associations between IL28B rs12979860 and survival since the start of RRT. A significant association was found in the case of IL28B rs8099917: GG carriers showed an increased risk of death compared with GT+TT carriers (FIGURE 2). Clinical and laboratory parameters evaluated in this study were not associated with the polymorphic variant rs8099917 of IL28B. FIGURE 2 Survival probability of hemodialysis patients with respect to IL28B 8099917 polymorphic variants Abbreviations:
levels than those observed in major allele homozygosity. 40 In the pilot study by Xenophontos et al., 41 rare IL13 rs20541 allele was associated with MI in Greek Cypriot males without impaired renal function. In our study on HD patients, the association between IL13 rs20541 showed only borderline significance for CAD. diabetic nephropathy, CAD or MI, but also the IL13 rs20541 T allele, IL28B rs12979860 TT genotype, and the GG genotype of IL28B rs8099917 may negatively influence survival in HD patients. IL13 rs20541 (Gln144Arg) is also known as +2044 G/A (Arg130Gln). Rare IL13 rs20541 allele homozygosity correlates with higher serum IL-13 FIGURE 4 Survival probability of hemodialysis patients negative for hepatitis B virus and hepatitis C virus infections with respect to IL28B 8099917 polymorphic variants Abbreviations:
IL-28B production compared with the CC genotype, 47 but how this may influence the development of CAD in HD patients without HBV or HCV infection remains unknown. Marco et al., 48 in a study on 143 patients, showed that VDR rs1544410 affects survival, while VDR rs2228570 does not. VDR and RXRA polymorphisms were associated with susceptibility to ESRD, and the GC rs7041 T allele was associated with a necessity to start RRT at a younger age.
49 There were also associations between vitamin D pathway gene polymorphisms and the prevalence of CAD or MI, mineral disorders, as well as severity of secondary hyperparathyroidism among patients of this group. 50 The VDR rs1 544410 AA genotype was shown to play a negative role (but not as an independent factor) in determining response to hepatitis B vaccination in patients from the study group. 51 Moreover, 2 of the tested SNPs of GC (rs7041, rs1155563) were identified as associated with 25(OH)D concentrations in a European population in a genome-wide association study.
52 Despite these
The major alleles of IL28B rs12979860 and rs8099917 SNPs promote spontaneous resolution of HCV infection.
42 Also a response to treatment with pegylated interferon and ribavirine is dependent on IL28B SNPs. 42, 43 Similar results were obtained for patients with HBV infection. 44 However, IL28B rs12979860 and rs8099917 seem not to be related to survival probability of HBV/HCV-infected patients on HD. Interestingly, HD individuals never infected with HBV or HCV showed a higher risk of death when carrying the IL28B rs12979860 TT or IL28B rs8099917 GG genotype. To our knowledge, such associations have not been documented so far. It was shown that the CC genotype of rs12979860 protects against HCV infection.
45 A possible relationship between IL28B rs12979860 and carotid atherosclerosis in patients with nonalcoholic fatty liver disease was investigated but no association was found. 46 Our results demonstrated an association of IL28B rs12979860 TT genotype with a higher prevalence of CAD in HD patients. The IL28B rs12979860 TT polymorphic variant was associated with lower and TABLE 1 findings, suggesting a possible association of vitamin D pathway gene polymorphisms with survival probability in patients on RRT, we did not reveal associations between GC rs7041, rs1155563 and rs2298849, VDR rs2228570 and rs1 544410, as well as RXRA rs10881578, rs10776909, and rs749759 polymorphic variants and survival either since the start of RRT or since birth. In summary, the IL13 rs20541 T allele and IL28B rs8099917 GG genotype are negative predictors of survival in patients on RRT; IL28B rs12979860 TT and IL28B 8099 917 GG genotypes are negatively associated with survival in patients on RRT negative for HBV or HCV infection seromarkers. In addition, the IL13 rs20541 T allele is an independent mortality risk factor among other clinical variables. In patients on RRT negative for HBV or HCV infection, the association of IL28B rs12979860 with survival may be at least partially explained by its relationship with the prevalence of CAD. Further studies are needed to establish which phenotypes of IL13 rs20541 and IL28B rs8099917 are associated with prediction of survival. Vitamin D pathway gene polymorphisms examined in this study are not predictors of survival probability in patients on RRT.
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